<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anesthesia and cancer recurrence
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anesthesia and cancer recurrence
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anesthesia and cancer recurrence
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Aislinn Sherwin, FCAI, BSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tom Wall, MSc, MD, FCAI
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donal J Buggy, DSc, MD, FRCPI, FCAI, FRCA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephanie B Jones, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marianna Crowley, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2875951382">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The possibility that anesthetic drugs and techniques may influence the risk of cancer recurrence is of widespread importance to patients and the clinicians who care for them. The number of cancer cases increased by &gt;25 percent globally between 2008 and 2018 [
         <a href="#rid1">
          1,2
         </a>
         ], and nearly two-thirds of patients diagnosed with cancer will undergo anesthesia and surgery for intended cure or palliation as first-line treatment [
         <a href="#rid3">
          3
         </a>
         ]. Thus, effects of anesthesia on cancer recurrence could have wide-ranging impact on population health.
        </p>
        <p>
         This topic will discuss the effects of anesthetic drugs and techniques that have been reported in laboratory, animal, and human studies, the proposed mechanisms for such effects, the limitations of existing literature, and implications for anesthetic practice.
        </p>
        <p class="headingAnchor" id="H1929154898">
         <span class="h1">
          MECHANISMS OF METASTASIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         While surgery is often performed with curative intent, tumor resection is a risk factor for metastasis. The spread of tumor cells into the circulation can occur before, during, or after the procedure, allowing for distant organ metastasis [
         <a href="#rid4">
          4
         </a>
         ]; minimal residual disease may remain and flourish even with clear resected surgical margins [
         <a href="#rid5">
          5,6
         </a>
         ]; localized spread of disease can occur within a body cavity; and tumor emboli can spread via the lymphatic system.
        </p>
        <p>
         Metastasis occurs when cancer cells are able to evade the immune system, proliferate, and invade tissues. The surgical period creates a tumorigenic physiologic environment, with potential for both direct and indirect effects on tumor cell survival. Multiple perioperative factors combine to create a state of relative immunosuppression, including the surgical stress response, the inflammatory response to surgery, and direct effects of anesthetics, opioids, and other perioperative medications. Hypothermia and blood transfusion can also suppress immune function. (See
         <a class="medical medical_review" href="/z/d/html/94588.html" rel="external">
          "Perioperative temperature management", section on 'Infection'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The physiologic stress response to surgery causes relative immunosuppression through the release of hormonal mediators (eg, catecholamines, prostaglandins, and growth factors) [
         <a href="#rid7">
          7
         </a>
         ]. Prostaglandins and catecholamines can cause activation of receptors that may increase the metastatic ability of cancer cells (eg, B2-adrenergic [
         <a href="#rid8">
          8
         </a>
         ] and cyclooxygenase-2 receptors [
         <a href="#rid9">
          9
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammation associated with tissue trauma causes the release of cytokines (eg, interleukin-6 and prostaglandins such as prostaglandin E2) that can cause inhibition of activity of natural killer (NK) cells [
         <a href="#rid10">
          10
         </a>
         ]. NK cells are essential in the perioperative phase as they are responsible for detecting and destroying circulating tumor cells [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Overcoming tissue hypoxia is central to growth of solid organ tumors, and cancer cells have adapted several pathways to ensure survival [
         <a href="#rid12">
          12
         </a>
         ]. Tissue hypoxia causes an upregulated expression of the transcription factor hypoxia-inducible factor 1-alpha (HIF1A), which is important in the promotion of cellular pathways for angiogenesis, cell proliferation, and metastasis [
         <a href="#rid13">
          13
         </a>
         ]. HIF1A causes downstream expression of vascular endothelial growth factor (VEGF) [
         <a href="#rid14">
          14
         </a>
         ], which in turn stimulates angiogenesis-promoting tumor growth [
         <a href="#rid15">
          15
         </a>
         ] and can promote remodeling of lymphatic pathways, allowing cell metastasis [
         <a href="#rid16">
          16
         </a>
         ]. High levels of HIF1A have been associated with poorer prognosis in a number of solid tumors [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The effects of anesthetics and anesthetic techniques on the mechanisms of metastasis are discussed in relevant sections below.
        </p>
        <p class="headingAnchor" id="H594521001">
         <span class="h1">
          EFFECTS OF ANESTHESIA
         </span>
        </p>
        <p class="headingAnchor" id="H2313754366">
         <span class="h2">
          State of the literature
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some laboratory and animal studies suggest an association between anesthetic drugs and techniques and the activity and survival of cancer cells, through changes in the immune response, modulation of the neuroendocrine stress response to surgery, or through effects on cancer cell signaling. However, high quality clinical outcome studies are few. Most existing clinical studies are retrospective; most prospective trials were initially designed to study outcomes other than cancer recurrence. However, several randomized trials have now been published [
         <a href="#rid17">
          17-20
         </a>
         ].
        </p>
        <p>
         Clinical trials of the effects of anesthetics on cancer are difficult to perform, as patients require a combination of anesthetic agents. In order to anaesthetize patients and provide analgesia, they are often managed with either inhalation agents and opioids, or
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         as the anesthetic agent and regional anesthesia as the analgesic agent. It would be difficult ethically to perform surgery without providing perioperative pain relief, or to perform surgery solely under regional anesthesia to separate out specific anesthetic modalities to study their effects.
        </p>
        <p class="headingAnchor" id="H3379878873">
         <span class="h3">
          Randomized trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several randomized trials have not found a beneficial effect of regional anesthesia techniques on cancer recurrence.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The first
         <strong>
         </strong>
         large randomized trial in this field compared two different anesthetic regimens for breast cancer surgery and was published in 2019 [
         <a href="#rid18">
          18
         </a>
         ]. Approximately 2100 patients who underwent mastectomy or wide local excision with axillary dissection were randomly assigned to receive regional anesthesia/analgesia (paravertebral block with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         sedation) or general anesthesia (
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         with opioid analgesia). Cancer recurrence was similar between patients who received regional anesthesia versus general anesthesia (hazard ratio 0.97, 95% CI 0.74-1.28), occurring in 10 percent of patients in each group over a median follow-up of 36 months. Whether these results can be applied to patients who undergo other cancer surgeries, particularly more extensive or painful procedures, is unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a follow-up analysis of data from a trial including over 1700 patients who underwent major abdominal or thoracic surgery and who were randomly assigned to epidural-general anesthesia versus general anesthesia alone with postoperative opioid analgesia, overall and recurrence free survival were similar in the two groups at over five year follow-up [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial including 400 patients who underwent video-assisted thoracoscopic surgery for lung cancer, recurrence free and overall survival were similar in patients who had general anesthesia with postoperative opioid analgesia, versus epidural-general anesthesia with postoperative epidural analgesia [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1324315700">
         <span class="h2">
          General anesthesia
         </span>
        </p>
        <p class="headingAnchor" id="H333275037">
         <span class="h3">
          Inhalation agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Volatile anesthetics —
         </strong>
         Laboratory studies have suggested some potential mechanisms whereby volatile anesthetics could enhance metastasis, including direct survival enhancing effects of volatile agents on cancer cells, and suppression of immune cell function and tumor cell killing [
         <a href="#rid21">
          21-24
         </a>
         ]. However, the molecular mechanisms for such effects are incompletely understood, and there is conflicting evidence among the inhaled agents and among different cancer cell lines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Volatile anesthetic agents (ie,
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         , halothane) also have proinflammatory effects [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Volatile agents may upregulate hypoxia-inducible factors, which may confer a cytoprotective effect for cancer cells perioperatively [
         <a href="#rid11">
          11
         </a>
         ].
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          Isoflurane
         </a>
         has been shown to upregulate hypoxia-inducible factor 1-alpha (HIF1A) and its downstream effectors in a prostate cell cancer line (PC3) in a dose-dependent manner [
         <a href="#rid13">
          13
         </a>
         ]. Similarly, renal cell carcinoma (RCC4) cells exposed to isoflurane demonstrated upregulated levels of HIF1A and vascular endothelial growth factor (VEGF) [
         <a href="#rid21">
          21
         </a>
         ]. In vitro studies of ovarian cancer cells found that exposure to isoflurane increased angiogenesis, cell proliferation, and migration associated with increased levels of insulin-like growth factor 1 and VEGF [
         <a href="#rid26">
          26
         </a>
         ]. Other studies of ovarian cancer cell lines have demonstrated increased expression of genes related to metastasis after exposure to
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         , and isoflurane [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In contrast, some studies have suggested a protective effect of the volatile agents and variable results in different cancers. In one study,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         produced chemoresistance to
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (a chemotherapeutic agent) in renal cell carcinoma cells; however, the opposite effect was seen in non-small cell lung cancer (NSCLC) cells [
         <a href="#rid28">
          28
         </a>
         ]. In another study, sevoflurane suppressed proliferation of breast cancer cells through cell cycle arrest at the G1 phase [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A 2016 systematic review of a number of animal studies suggested a link between volatile anesthesia and the number and incidence of metastases in experimental models [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         <strong>
          —
         </strong>
         There are very little data on the effects of nitrous oxide on cancer recurrence. In a secondary analysis of a trial that compared outcomes in patients who received nitrous oxide or nitrogen during
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         /
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         anesthesia for colon resection, approximately 400 patients who had surgery for cancer were followed for four to eight years postoperatively [
         <a href="#rid31">
          31
         </a>
         ]. There was no significant difference in cancer recurrence or mortality between groups.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3379959339">
         <span class="h3">
          Intravenous agents
         </span>
        </p>
        <p class="headingAnchor" id="H1671840320">
         <span class="h4">
          Propofol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         is the most commonly used intravenous induction agent and is often used for maintenance of anesthesia as well. Some preclinical evidence suggests that propofol may have antitumor effects. In laboratory studies, propofol exhibits antitumor effects by directly regulating key ribonucleic acid pathways and signaling in cancer cells [
         <a href="#rid32">
          32
         </a>
         ]. Propofol also has antiinflammatory and antioxidative effects [
         <a href="#rid33">
          33-38
         </a>
         ], which may protect against perioperative immune suppression.
        </p>
        <p>
         In vitro studies have demonstrated a variety of antitumor effects of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         in different cancer cell lines:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In gastric cancer cell lines
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         has been found to inhibit cell proliferation, invasion, and migration [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In NSCLC,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         was found to disrupt upregulation of HIF1A, thereby reducing the migration and invasion of the cancer cells [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In studies of breast cancer cell lines,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         reduced the expression of neuroepithelial cell transforming gene 1 (which is associated with promoting migration of adenocarcinoma in vitro [
         <a href="#rid41">
          41
         </a>
         ]), and increased cell apoptosis via the miR-24/p27 pathway [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In endometrial and esophageal squamous cell carcinoma cells,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         reduced expression of the sex-determining region Y-box (
         <em>
          SOX4
         </em>
         ) gene [
         <a href="#rid43">
          43,44
         </a>
         ], which is associated with poorer prognosis of some cancers [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In a study of the effects of anesthetics on natural killer (NK) cell activity and metastasis in a rat model of breast cancer,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         did not suppress NK cell activity or increase metastasis, whereas halothane,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , and thiopental did [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Perhaps a better live animal study used a murine allogenic model of breast cancer. This means that mouse breast cancer cells were cultured and inoculated into the breast tissue of another mouse to enable tumor to develop. These tumors were resected under the anaesthetic technique of interest. This “4T1” model involves injecting tumor cells from the same species, instead of injecting human breast cancer cells into a mouse or another animal, thereby avoiding the effect of a confounding immune response to non-species tissue. In this model,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         reduced lung metastasis compared with
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         and similarly to
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="local">
          'Lidocaine'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2562429014">
         <span class="h4">
          Other intravenous agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         and thiopental both demonstrate immune altering abilities. Both agents have been found to suppress NK cell activity [
         <a href="#rid48">
          48,49
         </a>
         ]. In a rat model, ketamine was found to induce tumour metastasis more effectively than other intravenous agents. The same study demonstrated an increase in metastasis while using thiopental, while
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         was protective [
         <a href="#rid46">
          46
         </a>
         ]. Ketamine tested on a human breast cancer cell line was found to upregulate levels of an anti-apoptosis protein, potentially increasing the ability of cells to invade and proliferate [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1695353312">
         <span class="h3">
          Intravenous versus inhalation anesthetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical studies (mostly retrospective) comparing intravenous and inhalation agents have reported mixed results, with some showing a beneficial effect of total intravenous anesthesia (TIVA) and others showing no effect compared with inhaled anesthetics [
         <a href="#rid51">
          51-60
         </a>
         ]. Proving a causal relationship between anesthetic technique and long-term oncologic outcomes requires large, prospective, randomized international trials, which are just starting to be done. (See
         <a class="local">
          'State of the literature'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Survival
         </strong>
         – A 2019 meta-analysis of six studies (five retrospective, one small randomized controlled trial) including over 7800 patients who underwent surgery for breast cancer, esophageal cancer, or NSCLC found that the use of TIVA was associated with improved recurrence–free survival, compared with volatile anesthesia (pooled hazard ratio [HR] 0.78, 95% CI 0.65-0.94) [
         <a href="#rid61">
          61
         </a>
         ]. However, interpretation of these results is limited by heterogeneity with respect to the extent of surgery, types of cancers, and patient characteristics, as well as other limitations associated with the retrospective nature of most of the studies. A subsequent retrospective Danish database analysis of over 8600 propensity matched patients undergoing surgery for colorectal cancer found an association between volatile anesthetic use and a small increase in cancer recurrence compared with TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (hazard ratio 1.12, 95% CI 1.02-1.13) [
         <a href="#rid62">
          62
         </a>
         ]. There was no difference in overall survival.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Circulating tumor cells
         </strong>
         – A randomized trial of 210 women who underwent breast cancer surgery reported similar circulating postoperative tumor cell counts in patients who received
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         versus
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         anesthesia [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune cells
         </strong>
         – In a randomized trial of 153 patients who underwent surgery for resection of colorectal cancer, the fractions of postoperative circulating natural killer cells, helper T cells, and cytotoxic T cells were similar in patients who had
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         versus
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         for anesthesia propofol or sevoflurane anesthesia. [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cancer regulatory factors
         </strong>
         – In vivo studies of the effects of intravenous versus inhalation agents on cancer regulatory factors have reported conflicting results. A small study of pro-oncogenic gene expression in patients who underwent resection for head and neck cancer found that those who received volatile agents had significant increases in expression of HIF1A [
         <a href="#rid65">
          65
         </a>
         ]. In contrast, another study of patients who underwent surgery for breast cancer reported no difference in expression of regulatory T cell enzymes that promote cancer recurrence in patients who received volatile versus intravenous anesthesia [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A number of studies have assessed the response of different cancer cell lines when exposed to serum from patients who have undergone either volatile anesthesia or combined regional and
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         anesthesia. In one such study, LoVo colon cancer cells were exposed to serum from 40 patients who underwent colon cancer resection with either a thoracic epidural/propofol technique or
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         /opioid analgesia technique [
         <a href="#rid67">
          67
         </a>
         ]. Serum from those receiving the regional and propofol technique inhibited the proliferation and invasion of incubated cancer cells and showed higher rates of cell apoptosis than those receiving volatile and opioid analgesia [
         <a href="#rid67">
          67
         </a>
         ]. In another study, serum from women who underwent breast cancer resection using either propofol/paravertebral block anesthesia or sevoflurane/opioid anesthesia demonstrated a preservation of NK cell activity and increased cancer cell apoptosis in those who had propofol/paravertebral block [
         <a href="#rid22">
          22,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2935775481">
         <span class="h2">
          Regional anesthesia/analgesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effects of regional anesthesia or analgesia on cancer recurrence seem to be equivalent to general anesthesia [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="local">
          'Randomized trials'
         </a>
         above.)
        </p>
        <p>
         Regional anesthesia/analgesia could reduce cancer recurrence via several mechanisms: by reducing the stress response to surgery (via pain control or sympathetic block) [
         <a href="#rid68">
          68,69
         </a>
         ], by reducing the need for opioids or volatile agents, or via direct effects of absorbed local anesthetics (see
         <a class="local">
          'Lidocaine'
         </a>
         below). However, there is no high-quality evidence in humans that confirms a beneficial effect of regional anesthesia on cancer recurrence. The first large international randomized trial of regional anesthesia/
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         versus general anesthesia with
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         /opioids found similar rates of recurrence after breast cancer surgery [
         <a href="#rid18">
          18
         </a>
         ] and two other studies found a similar effect of epidural regional anesthesia compared with IV opioid [
         <a href="#rid19">
          19,20
         </a>
         ](see
         <a class="local">
          'State of the literature'
         </a>
         above). Most other existing studies are retrospective or small, and meta-analyses include heterogeneous cancers, surgical technique, patient populations, and follow-up.
        </p>
        <p>
         A 2014 meta-analysis with data from over 3000 patients found no associated difference in cancer recurrence or survival in patients who received general-epidural anesthesia versus general anesthesia alone [
         <a href="#rid70">
          70
         </a>
         ]. Similarly, a 2017 meta-analysis of 28 studies (retrospective, observational, and randomized) including over 67,000 patients who underwent surgery for a variety of cancers found similar recurrence-free survival, overall survival, and biochemical recurrence-free survival in patients who had regional anesthesia with or without general anesthesia and those who had general anesthesia alone [
         <a href="#rid71">
          71
         </a>
         ]. A meta-analysis of 10 retrospective studies including approximately 13,760 patients who underwent radical prostatectomy for cancer found that regional anesthesia with or without general anesthesia was associated with improved overall survival, but similar cancer recurrence, compared with general anesthesia alone [
         <a href="#rid72">
          72
         </a>
         ]. A further meta-analysis has suggested that neuraxial anesthesia may be associated with improved overall survival, particularly in patients with colorectal cancer, as well as reduced risk of cancer recurrence [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         As discussed in an earlier section, serum from patients undergoing surgery for breast cancer using either
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and paravertebral regional technique or opioid and volatile technique was examined in a number of studies in terms of immune effect. Those receiving a combined regional and intravenous agent technique demonstrated increased levels of immune cell infiltration into breast cancer tissue, increased levels of cancer cell apoptosis, and preserved NK cell cytotoxicity [
         <a href="#rid22">
          22,23,34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2574156410">
         <span class="h1">
          EFFECTS OF ADJUVANT DRUGS ADMINISTERED DURING ANESTHESIA
         </span>
        </p>
        <p class="headingAnchor" id="H1586500281">
         <span class="h2">
          Opioids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory studies suggest several mechanisms by which opioids might influence metastasis or tumor growth. However, the evidence is conflicting and inconsistent across opioids, and the limited clinical data on the effects of perioperative opioids are inconclusive. Examples of relevant studies and concepts are discussed here.
        </p>
        <p class="headingAnchor" id="H358024159">
         <span class="h3">
          Preclinical evidence
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preclinical studies have found that some but not all opioids have immunosuppressive properties, including reduced natural killer (NK) cell cytotoxicity and impairment of neutrophil chemotaxis [
         <a href="#rid74">
          74,75
         </a>
         ]. Opioids may act directly on cells of the immune system (eg, lymphocytes and mononuclear phagocytes) through opioid receptors or via nonopioid receptors (eg, toll-like receptor 4) [
         <a href="#rid76">
          76
         </a>
         ]. In a murine model of breast cancer,
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         stimulated mast cell activation, which may accelerate cancer progression, via increased concentrations of substance P and cytokines [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         NK cells may also be affected by
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         . In a study of 80 patients who underwent resection of rectal cancer, administration of either morphine or
         <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">
          oxycodone
         </a>
         was associated with reduced serum counts of NK cells and T lymphocytes for 6 to 12 hours after opioid injection [
         <a href="#rid78">
          78
         </a>
         ]. A small study of NK cell activity in the serum of women undergoing breast cancer surgery found reduced in vitro NK cell cytotoxicity in patients who received
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         /opioid anesthesia, compared with those who received
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         with regional anesthesia [
         <a href="#rid22">
          22
         </a>
         ]. In another study of the same patient cohort, patients who were randomly assigned to receive sevoflurane/opioid anesthesia had a higher postoperative neurophil-lymphocyte ratio (a marker of increased risk of recurrence and poor outcome) than patients who received propofol with regional anesthesia [
         <a href="#rid79">
          79
         </a>
         ]. Similar to a number of other clinical trials, the effects of individual anesthetic agents cannot be determined (eg, sevoflurane versus opioids).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioids can also interact with inflammatory cytokines (interleukin [IL] 1, IL-4, IL-6, and tumor necrosis factor), which control gene expression at the mu-opioid receptor (MOR) [
         <a href="#rid80">
          80
         </a>
         ]. In pathologic samples of excised breast cancer tissue, those receiving a
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and paravertebral anesthesia technique had more infiltration of NK cells and T helper cells than those who received a general anesthetic with opioid analgesia, suggesting that the opioid techniques may suppress immune activation [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioids may directly influence cancer cell growth via their action on MOR [
         <a href="#rid76">
          76,81,82
         </a>
         ], which are overexpressed on the surface of certain cancer cell lines [
         <a href="#rid83">
          83-85
         </a>
         ]. In a study of biopsy specimens from 34 patients with lung cancer, MOR expression was increased twofold in patients with metastatic disease, compared with those without metastasis [
         <a href="#rid84">
          84
         </a>
         ]. Overexpression of MOR has been associated with reduced overall survival and reduced progression-free survival in prostate cancer patients [
         <a href="#rid86">
          86
         </a>
         ]. In a study of patients with breast cancer, those with a MOR gene polymorphism had decreased cancer-related mortality over 10 years [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Consistent with the role of the MOR in cancer progression,
         <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">
          methylnaltrexone
         </a>
         , a MOR antagonist, may have beneficial effects in halting cancer progression and metastasis. In a post hoc analysis of two randomized trials, patients with end stage cancer treated with methylnaltrexone for opioid induced constipation had improved overall survival, compared with patients who did not receive methylnaltrexone [
         <a href="#rid88">
          88
         </a>
         ]. In a laboratory study of non-small cell lung cancer (NSCLC) cell lines, treatment with methylnaltrexone inhibited invasion of cancer cells [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The effects of opioids on cancer cell biology are variable and conflicting among various opioids, and in some cases have been shown to be protective. In mouse models,
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         has been shown to have anti-tumor or antimetastatic effects in breast cancer [
         <a href="#rid90">
          90-92
         </a>
         ]. Antitumor effects of D,L
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         have been reported in glioblastoma [
         <a href="#rid93">
          93
         </a>
         ] and leukemia models [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3578075821">
         <span class="h3">
          Clinical studies: complex link between perioperative opioids and oncologic outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Available evidence on the effect of intraoperative opioid use and long-term oncologic outcome is complex, conflicting, and limited to laboratory or observational studies. There is at present no justification for any change in perioperative opioid prescribing practice on the basis that it might affect cancer recurrence.
        </p>
        <p>
         Clinical studies of the effects of intraoperative or postoperative opioids on cancer recurrence have reported conflicting results. Until recently, the prevailing trend in experimental and observational studies was that opioid use during cancer resection surgery was associated with negative oncologic outcomes. However, several retrospective database studies from the same institution suggest a potentially differential effect of opioids in cancer subtypes, which may also be applicable to other tumors [
         <a href="#rid95">
          95,96
         </a>
         ]. In one of these studies, characteristics of resected breast cancer tissue were analyzed for over 1100 women with triple negative breast cancer (TNBC), which is notoriously difficult to treat if it recurs [
         <a href="#rid95">
          95
         </a>
         ]. The investigators identified opioid receptor expression in the TNBC tumors and correlated it with clinical anesthesia management and oncologic outcomes. Higher intraoperative opioid dose was associated with improved recurrence free survival (hazard ratio [HR] 0.93, 95% CI 0.88-0.99, per 10
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         milligram equivalent [MME] increase), but this was not significantly associated with improved overall survival.
        </p>
        <p>
         Examples of other relevant studies include the following.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another retrospective study involving approximately 900 patients who underwent surgery for NSCLC found that higher intraoperative
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         doses were associated with reduced overall survival (OS) for patients with early stage cancer, but not for patients with more advanced cancer [
         <a href="#rid97">
          97
         </a>
         ]. Yet another retrospective study including approximately 2800 patients who underwent surgery for renal cell carcinoma, higher intraoperative opioid administration was associated with reduced recurrence free survival (HR 1.06 per 10 MME, 95% CI 1.03-1.09), and reduced OS (HR 1.05 per 10 MME, 95% CI 1.02-1.09) [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, in a retrospective study including approximately 1680 patients who underwent resection of colorectal cancer, the intraoperative dose of
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         was not associated with the risk of recurrence or overall survival [
         <a href="#rid99">
          99
         </a>
         ]. Similarly, a retrospective study of postoperative opioid administration in 1000 patients who underwent surgery for NSCLC found that increasing opioid dose was not associated with an increase in the risk of recurrence or death [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2018 systematic review of the literature regarding perioperative opioids and colorectal cancer recurrence included 13 studies, with inconclusive results [
         <a href="#rid101">
          101
         </a>
         ]. Meta-analysis was not possible due to low quality data.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1243447874">
         <span class="h2">
          Lidocaine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         is commonly administered during anesthesia as a component of multimodal analgesia. There is strong in vitro evidence of a protective effect of systemic lidocaine on cancer recurrence, though there are limited relevant clinical data.
        </p>
        <p>
         Laboratory and human studies have demonstrated that local anesthetics have antiinflammatory properties [
         <a href="#rid102">
          102
         </a>
         ].
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         has been shown to reduce levels of the inflammatory markers IL-1, tumor necrosis factor-alpha, and IL-8, in addition to direct effects on cancer cells via blockade of voltage-gated sodium channels on tumor cells or other mechanisms [
         <a href="#rid103">
          103,104
         </a>
         ]. Lidocaine reduces cancer cell viability and migration in laboratory studies, and improved survival in the 4T1 allogeneic mouse model of breast cancer [
         <a href="#rid105">
          105
         </a>
         ]. In these studies, intravenous lidocaine reduced the volume of lung metastasis when combined with volatile anesthesia [
         <a href="#rid106">
          106
         </a>
         ], potentially mitigating the effects of volatile anesthesia. In another study using the same murine model, the addition of lidocaine to the chemotherapeutic agent
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         resulted in a reduction in metastatic lung colony counts compared with control or cisplatin alone [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
         Retrospective clinical studies suggest an association between intraoperative IV
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         and improved outcomes after cancer surgery, though conclusions are limited by their retrospective design and unknown surgical variables. (See
         <a class="local">
          'State of the literature'
         </a>
         above.)
        </p>
        <p>
         Examples include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of approximately 2000 patients who underwent surgery for pancreatic cancer, disease-free survival after surgery was similar in patients who received intraoperative
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         (bolus 1.5 mg/kg IV at induction, followed by infusion at 2 mg/kg/hour IV) and those who received no lidocaine [
         <a href="#rid108">
          108
         </a>
         ]. Lidocaine infusion was associated with a modest increase in overall survival at one and three years (overall survival at one year, 68 versus 63 percent, overall survival at three years 34 versus 27 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another retrospective study of 144 patients who underwent radical cystectomy for bladder cancer, intraoperative IV
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         was associated with reduced overall mortality (adjusted hazard ratio 0.36, 95% CI 0.12-0.83) and reduced incidence of cancer recurrence (30 versus 47 percent) within two years, compared with patients who did not receive lidocaine [
         <a href="#rid109">
          109
         </a>
         ]. Lidocaine was administered as a bolus of 1 mg/kg IV followed by infusion at 1.5 mg/kg/hour IV, stopped one hour prior to the end of surgery.
        </p>
        <p>
        </p>
        <p>
         The VAPOR-C trial is a large, international, randomized controlled trial which commenced in 2021 after promising pilot-feasibility studies [
         <a href="#rid110">
          110
         </a>
         ]. This trial is comparing
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         versus
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         general anesthesia, with or without IV
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , in a 2x2 factorial design.
        </p>
        <p class="headingAnchor" id="H2346888945">
         <span class="h2">
          Nonsteroidal antiinflammatory drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several retrospective studies suggest that intraoperative administration of nonsteroidal antiinflammatory drugs (NSAIDs) during cancer surgery may reduce recurrence and improve survival. A retrospective single institution study of 720 women who underwent breast lumpectomy with or without axillary node dissection for cancer found an association between intraoperative administration of
         <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">
          ketorolac
         </a>
         or
         <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">
          diclofenac
         </a>
         and longer disease-free and overall survival [
         <a href="#rid111">
          111
         </a>
         ]. Similarly, a retrospective study of 327 women who underwent mastectomy with axillary lymph node dissection reported lower cancer recurrence rates in patients who received intraoperative ketorolac compared with those who received
         <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">
          sufentanil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
         In one small prospective trial, 38 patients were randomly assigned to receive
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         and
         <a class="drug drug_general" data-topicid="8427" href="/z/d/drug information/8427.html" rel="external">
          etodolac
         </a>
         or placebo for five days before and after lumpectomy or mastectomy for breast cancer [
         <a href="#rid113">
          113
         </a>
         ]. Markers of cellular and molecular pathways associated with cancer recurrence were reduced in patients who received the drug combination.
        </p>
        <p>
         Long term use of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and other NSAIDs is associated with reduced incidence of death from colorectal and possibly some other cancers. The mechanisms for these benefits and supporting evidence are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">
          "Aspirin in the primary prevention of cardiovascular disease and cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/792.html" rel="external">
          "Factors that modify breast cancer risk in women", section on 'Nonsteroidal anti-inflammatory drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2869319021">
         <span class="h2">
          Alpha-2 adrenoceptor agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alpha-2 adrenoreceptors may play a role in the development of breast cancer.
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         is a selective alpha-2 adrenoceptor agonist that is increasingly used in the perioperative period, particularly in low doses for sedation. Low dose
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , which is an older alpha-2 receptor agonist, is used as part of multimodal opioid-sparing analgesia. The literature regarding dexmedetomidine and/or clonidine and cancer recurrence is limited, and further study is required before drawing conclusions on their use.
        </p>
        <p>
         A retrospective single center study of 250 patients who underwent surgery for NSCLC reported that duration of recurrent-free survival was similar in patients who received intraoperative
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         and those who did not, though dexmedetomidine was associated with reduced overall survival [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
         A laboratory study of the effect of
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         in rat models of lung, breast, and colon cancer found a dose-dependent increase on tumor cell retention and metastasis, which is thought to be mediated through stimulation of the alpha-2 adrenoceptors [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
         In a retrospective study of approximately 650 patients who underwent surgery for breast or lung cancer, recurrence-free survival and overall survival were similar in patients who received low dose
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         intraoperatively and those who did not receive clonidine [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1040624967">
         <span class="h2">
          Beta blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benefits of perioperative beta blockers on cancer recurrence have not been determined. Beta blockers may be administered during surgery to counteract catecholamine-mediated effects of the stress response to surgery. Laboratory studies have reported anti-tumor effects of beta blockers, including reduced proliferation of liver cancer cells [
         <a href="#rid117">
          117
         </a>
         ] and preserved NK cell function when combined with NSAIDs [
         <a href="#rid118">
          118
         </a>
         ]. In a study of patients who underwent breast cancer surgery, perioperative administration of
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         attenuated the surgery-related increase in regulatory T cells (which suppress antitumor immunity) [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
         The clinical studies of the effects of beta blockers on cancer recurrence are inconclusive. A 2018 meta-analysis of 27 mostly retrospective studies (10 perioperative, the remainder epidemiologic) found that cancer recurrence was similar in patients who received beta blockers and those who did not [
         <a href="#rid120">
          120
         </a>
         ]. Beneficial effects were possible in some tumor types, but the overall quality of the data was low.
        </p>
        <p>
         In a 2015 meta-analysis of seven cohort studies in patients with breast cancer, the use of beta blockers was associated with reduced risk of breast cancer-related death (hazard ratio [HR] 0.50, 95% CI, 0.32-0.80), but similar risk of cancer recurrence and all-cause mortality, compared with patients who did not use beta blockers [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4055331239">
         <span class="h2">
          Dexamethasone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids have antiinflammatory effects, which could be beneficial with respect to cancer recurrence, but also have immune modulating effects, which could reduce cancer cell killing.
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         is widely administered during anesthesia for prevention of postoperative nausea and vomiting and as an adjunct for analgesia. There is insufficient evidence to support a change in this practice based on concern for cancer recurrence.
        </p>
        <p>
         The existing limited laboratory and clinical evidence is conflicting. In a preclinical study involving several different cancer cell lines,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         was associated with increase proliferation of some solid tumor cell lines, but not others [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
         In retrospective studies of women who underwent cytoreductive surgery for ovarian cancer [
         <a href="#rid123">
          123
         </a>
         ], and surgery for endometrial cancer [
         <a href="#rid124">
          124
         </a>
         ], cancer recurrence was similar in patients who did and did not receive intraoperative
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (4 to 10 mg intravenous [IV]) [
         <a href="#rid123">
          123
         </a>
         ]. In a retrospective study of patients who underwent surgery for NSCLC, intraoperative dexamethasone was associated with longer survival after surgery [
         <a href="#rid125">
          125
         </a>
         ]. In contrast, in a retrospective study of approximately 500 patients who underwent surgery for rectal cancer, intraoperative dexamethasone was associated with shorter disease-free survival [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
         Glucocorticoids are also widely used for prevention of chemotherapy-induced nausea and vomiting and as adjuvant therapy for pain control in patients with known metastatic cancer, without concern for worsening disease. (See
         <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">
          "Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1911045748">
         <span class="h2">
          Oxygen
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of oxygen administration in postoperative cancer recurrence is unclear. Supplemental oxygen is routinely administered during anesthesia; the total amount of oxygen exposure during anesthesia should be limited, and fraction of inspired oxygen (FiO
         <sub>
          2
         </sub>
         ) of 0.3 to 0.4 should provide adequate oxygenation with a margin of safety for most patients. (See
         <a class="medical medical_review" href="/z/d/html/93386.html" rel="external">
          "Mechanical ventilation during anesthesia in adults", section on 'Fraction of inspired oxygen'
         </a>
         .)
        </p>
        <p>
         As discussed above, tissue hypoxia is involved in important mechanisms for angiogenesis and tumor progression (see
         <a class="local">
          'Mechanisms of metastasis'
         </a>
         above). However, hyperoxia may also facilitate proliferation of tumor cells via positive effects on angiogenesis [
         <a href="#rid127">
          127
         </a>
         ] and the formation of reactive oxygen species that may damage DNA [
         <a href="#rid128">
          128
         </a>
         ]. Such mechanisms are complex and have not been fully elucidated.
        </p>
        <p>
         In vitro studies have reported that exposure to high concentration of oxygen can increase the migration and secretion of angiogenesis factors of breast cancer cells [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
         The effect of FiO
         <sub>
          2
         </sub>
         on the risk of new or recurrent cancer was investigated in a post hoc analysis of the PROXI trial, in which patients who underwent abdominal surgery (approximately one-half for cancer) were randomly assigned to receive 30 percent or 80 percent oxygen during and for two hours after surgery [
         <a href="#rid130">
          130
         </a>
         ]. The overall frequency of new cancers was similar between groups. However, the time to diagnosis of a new cancer and cancer-free survival were shorter in patients who received 80 percent oxygen.
        </p>
        <p class="headingAnchor" id="H4090093006">
         <span class="h1">
          IMPLICATIONS FOR PRACTICE
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is evidence from laboratory, animal, and retrospective human studies that anesthetic agents may affect cancer recurrence. However, there is insufficient evidence to suggest a change in anesthetic practice or the use of specific agents for the purpose of reducing the risk of cancer recurrence in patients who undergo cancer surgery.
        </p>
        <p class="headingAnchor" id="H923229059">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whereas laboratory, animal, and retrospective human data suggest that anesthetic agents may affect cancer recurrence, there is insufficient evidence to suggest the use of specific anesthetic agents or techniques to reduce the risk of cancer recurrence in patients who undergo cancer surgery. (See
         <a class="local">
          'Implications for practice'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The perioperative period is associated with multiple factors that may influence tumor cell survival, including the inflammatory and stress responses to surgery, relative immunosuppression, and possible direct effects of anesthetics, opioids, and other perioperative medications. (See
         <a class="local">
          'Mechanisms of metastasis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A body of laboratory and animal studies suggests an association between anesthetic drugs and techniques and the activity and survival of cancer cells. Most existing clinical studies are retrospective or were initially designed to study outcomes other than cancer recurrence, and are therefore inconclusive with respect to cancer recurrence. (See
         <a class="local">
          'State of the literature'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Volatile anesthetics have proinflammatory effects, and may have direct and indirect effects on cancer cell survival, including immune suppression and upregulation of hypoxia-inducible factors (H1F1-A). However, the laboratory, animal, and human studies on cancer recurrence after the use of volatile agents are conflicting. (See
         <a class="local">
          'Inhalation agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         may have antiinflammatory and antioxidative effects that protect against immune suppression and may preserve natural killer (NK) cell activity. (See
         <a class="local">
          'Propofol'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical studies that have compared intravenous and inhalation anesthetic agents have shown mixed results regarding cancer recurrence. (See
         <a class="local">
          'Intravenous versus inhalation anesthetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regional anesthesia could reduce cancer recurrence by reducing the need for opioids or volatile anesthetics, or reducing the stress response to surgery. However, several randomized trials have not confirmed a beneficial effect. (See
         <a class="local">
          'Randomized trials'
         </a>
         above and
         <a class="local">
          'Regional anesthesia/analgesia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory studies suggest that opioids might influence metastasis or tumor growth. However, the evidence is conflicting and inconsistent across opioids, and the limited clinical data on the effects of perioperative opioids are inconclusive. (See
         <a class="local">
          'Opioids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is strong in vitro evidence of a protective effect of systemic
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         on cancer recurrence, though there is limited relevant clinical data. (See
         <a class="local">
          'Lidocaine'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2018; 4:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359.
          </a>
         </li>
         <li class="breakAll">
          Data collected in more than 1500 Commission on Cancer (CoC) accredited facilities, sorted by first course treatment and data from 2007-2016. National Cancer Database (NCDB). American College of Surgeons and the American Cancer Society. Available at: https://www.facs.org/quality-programs/cancer/ncdb (Accessed on May 27, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engilbertsson H, Aaltonen KE, Björnsson S, et al. Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol 2015; 193:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth 2012; 109 Suppl 1:i17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wall T, Sherwin A, Ma D, Buggy DJ. Influence of perioperative anaesthetic and analgesic interventions on oncological outcomes: a narrative review. Br J Anaesth 2019; 123:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alazawi W, Pirmadjid N, Lahiri R, Bhattacharya S. Inflammatory and Immune Responses to Surgery and Their Clinical Impact. Ann Surg 2016; 264:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, et al. Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res 2010; 19:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu WK, Sung JJ, Lee CW, et al. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett 2010; 295:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angka L, Khan ST, Kilgour MK, et al. Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery. Int J Mol Sci 2017; 18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tavare AN, Perry NJ, Benzonana LL, et al. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer 2012; 130:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 2015; 5:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang H, Benzonana LL, Zhao H, et al. Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination. Br J Cancer 2014; 111:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darby IA, Hewitson TD. Hypoxia in tissue repair and fibrosis. Cell Tissue Res 2016; 365:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schito L, Semenza GL. Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. Trends Cancer 2016; 2:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karnezis T, Shayan R, Caesar C, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 2012; 21:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buggy DJ, Riedel B, Sessler DI. Can anaesthetic technique influence cancer outcome? The next steps…. Br J Anaesth 2021; 127:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sessler DI, Pei L, Huang Y, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet 2019; 394:1807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du YT, Li YW, Zhao BJ, et al. Long-term Survival after Combined Epidural-General Anesthesia or General Anesthesia Alone: Follow-up of a Randomized Trial. Anesthesiology 2021; 135:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu ZZ, Li HJ, Li MH, et al. Epidural Anesthesia-Analgesia and Recurrence-free Survival after Lung Cancer Surgery: A Randomized Trial. Anesthesiology 2021; 135:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benzonana LL, Perry NJ, Watts HR, et al. Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. Anesthesiology 2013; 119:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckley A, McQuaid S, Johnson P, Buggy DJ. Effect of anaesthetic technique on the natural killer cell anti-tumour activity of serum from women undergoing breast cancer surgery: a pilot study. Br J Anaesth 2014; 113 Suppl 1:i56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desmond F, McCormack J, Mulligan N, et al. Effect of anaesthetic technique on immune cell infiltration in breast cancer: a follow-up pilot analysis of a prospective, randomised, investigator-masked study. Anticancer Res 2015; 35:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ecimovic P, McHugh B, Murray D, et al. Effects of sevoflurane on breast cancer cell function in vitro. Anticancer Res 2013; 33:4255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurosawa S, Kato M. Anesthetics, immune cells, and immune responses. J Anesth 2008; 22:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo X, Zhao H, Hennah L, et al. Impact of isoflurane on malignant capability of ovarian cancer in vitro. Br J Anaesth 2015; 114:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwasaki M, Zhao H, Jaffer T, et al. Volatile anaesthetics enhance the metastasis related cellular signalling including CXCR2 of ovarian cancer cells. Oncotarget 2016; 7:26042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciechanowicz S, Zhao H, Chen Q, et al. Differential effects of sevoflurane on the metastatic potential and chemosensitivity of non-small-cell lung adenocarcinoma and renal cell carcinoma in vitro. Br J Anaesth 2018; 120:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Yang L, Guo X, et al. Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells. Mol Med Rep 2018; 18:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooijmans CR, Geessink FJ, Ritskes-Hoitinga M, Scheffer GJ. A Systematic Review of the Modifying Effect of Anaesthetic Drugs on Metastasis in Animal Models for Cancer. PLoS One 2016; 11:e0156152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleischmann E, Marschalek C, Schlemitz K, et al. Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial. BMC Anesthesiol 2009; 9:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang S, Liu Y, Huang L, et al. Effects of propofol on cancer development and chemotherapy: Potential mechanisms. Eur J Pharmacol 2018; 831:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim R. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Rev 2017; 36:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaura AI, Flood G, Gallagher HC, Buggy DJ. Differential effects of serum from patients administered distinct anaesthetic techniques on apoptosis in breast cancer cells in vitro: a pilot study. Br J Anaesth 2014; 113 Suppl 1:i63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Liang M, Zhu Y, Zhou D. [The effect of propofol and sevoflurane on the perioperative immunity in patients under laparoscopic radical resection of colorectal cancer]. Zhonghua Yi Xue Za Zhi 2015; 95:3440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baki ED, Aldemir M, Kokulu S, et al. Comparison of the effects of desflurane and propofol anesthesia on the inflammatory response and s100β protein during coronary artery bypass grafting. Inflammation 2013; 36:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu S, Gu X, Zhu L, et al. Effects of propofol and sevoflurane on perioperative immune response in patients undergoing laparoscopic radical hysterectomy for cervical cancer. Medicine (Baltimore) 2016; 95:e5479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu TC. Influence of propofol, isoflurane and enflurance on levels of serum interleukin-8 and interleukin-10 in cancer patients. Asian Pac J Cancer Prev 2014; 15:6703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang C, Gao J, Yan N, et al. Propofol inhibits the growth and survival of gastric cancer cells in vitro through the upregulation of ING3. Oncol Rep 2017; 37:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang N, Liang Y, Yang P, Ji F. Propofol suppresses LPS-induced nuclear accumulation of HIF-1α and tumor aggressiveness in non-small cell lung cancer. Oncol Rep 2017; 37:2611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ecimovic P, Murray D, Doran P, Buggy DJ. Propofol and bupivacaine in breast cancer cell function in vitro - role of the NET1 gene. Anticancer Res 2014; 34:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu B, Gao W, Zhou H, et al. Propofol induces apoptosis of breast cancer cells by downregulation of miR-24 signal pathway. Cancer Biomark 2018; 21:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du Q, Liu J, Zhang X, et al. Propofol inhibits proliferation, migration, and invasion but promotes apoptosis by regulation of Sox4 in endometrial cancer cells. Braz J Med Biol Res 2018; 51:e6803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou CL, Li JJ, Ji P. Propofol Suppresses Esophageal Squamous Cell Carcinoma Cell Migration and Invasion by Down-Regulation of Sex-Determining Region Y-box 4 (SOX4). Med Sci Monit 2017; 23:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen J, Ju HL, Yuan XY, et al. SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis. Clin Transl Oncol 2016; 18:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melamed R, Bar-Yosef S, Shakhar G, et al. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg 2003; 97:1331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman J, Crowley PD, Foley AG, et al. Effect of Perioperative Lidocaine, Propofol and Steroids on Pulmonary Metastasis in a Murine Model of Breast Cancer Surgery. Cancers (Basel) 2019; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forget P, Collet V, Lavand'homme P, De Kock M. Does analgesia and condition influence immunity after surgery? Effects of fentanyl, ketamine and clonidine on natural killer activity at different ages. Eur J Anaesthesiol 2010; 27:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishina K, Akamatsu H, Mikawa K, et al. The inhibitory effects of thiopental, midazolam, and ketamine on human neutrophil functions. Anesth Analg 1998; 86:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He H, Chen J, Xie WP, et al. Ketamine used as an acesodyne in human breast cancer therapy causes an undesirable side effect, upregulating anti-apoptosis protein Bcl-2 expression. Genet Mol Res 2013; 12:1907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wigmore TJ, Mohammed K, Jhanji S. Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer Surgery: A Retrospective Analysis. Anesthesiology 2016; 124:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enlund M, Berglund A, Andreasson K, et al. The choice of anaesthetic--sevoflurane or propofol--and outcome from cancer surgery: a retrospective analysis. Ups J Med Sci 2014; 119:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JH, Kang SH, Kim Y, et al. Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: a retrospective study. Korean J Anesthesiol 2016; 69:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh TK, Kim K, Jheon S, et al. Long-Term Oncologic Outcomes for Patients Undergoing Volatile Versus Intravenous Anesthesia for Non-Small Cell Lung Cancer Surgery: A Retrospective Propensity Matching Analysis. Cancer Control 2018; 25:1073274818775360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai HC, Lee MS, Lin C, et al. Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in hepatectomy for hepatocellular carcinoma: a retrospective cohort study. Br J Anaesth 2019; 123:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh TK, Kim HH, Jeon YT. Retrospective analysis of 1-year mortality after gastric cancer surgery: Total intravenous anesthesia versus volatile anesthesia. Acta Anaesthesiol Scand 2019; 63:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo S, Lee HB, Han W, et al. Total Intravenous Anesthesia versus Inhalation Anesthesia for Breast Cancer Surgery: A Retrospective Cohort Study. Anesthesiology 2019; 130:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enlund M, Berglund A, Ahlstrand R, et al. Survival after primary breast cancer surgery following propofol or sevoflurane general anesthesia-A retrospective, multicenter, database analysis of 6305 Swedish patients. Acta Anaesthesiol Scand 2020; 64:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makito K, Matsui H, Fushimi K, Yasunaga H. Volatile versus Total Intravenous Anesthesia for Cancer Prognosis in Patients Having Digestive Cancer Surgery. Anesthesiology 2020; 133:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enlund M, Berglund A, Enlund A, Bergkvist L. Volatile versus Propofol General Anesthesia and Long-term Survival after Breast Cancer Surgery: A National Registry Retrospective Cohort Study. Anesthesiology 2022; 137:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yap A, Lopez-Olivo MA, Dubowitz J, et al. Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth 2019; 66:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasselager RP, Hallas J, Gögenur I. Inhalation or total intravenous anaesthesia and recurrence after colorectal cancer surgery: a propensity score matched Danish registry-based study. Br J Anaesth 2021; 126:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hovaguimian F, Braun J, Z'graggen BR, et al. Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial. Anesthesiology 2020; 133:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh CS, Park HJ, Piao L, et al. Expression Profiles of Immune Cells after Propofol or Sevoflurane Anesthesia for Colorectal Cancer Surgery: A Prospective Double-blind Randomized Trial. Anesthesiology 2022; 136:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrell JK, Cattano D, Brown RE, et al. The effects of anesthesia on the morphoproteomic expression of head and neck squamous cell carcinoma: a pilot study. Transl Res 2015; 166:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh CS, Lee J, Yoon TG, et al. Effect of Equipotent Doses of Propofol versus Sevoflurane Anesthesia on Regulatory T Cells after Breast Cancer Surgery. Anesthesiology 2018; 129:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu YJ, Li SY, Cheng Q, et al. Effects of anaesthesia on proliferation, invasion and apoptosis of LoVo colon cancer cells in vitro. Anaesthesia 2016; 71:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahnenkamp K, Herroeder S, Hollmann MW. Regional anaesthesia, local anaesthetics and the surgical stress response. Best Pract Res Clin Anaesthesiol 2004; 18:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Riain SC, Buggy DJ, Kerin MJ, et al. Inhibition of the stress response to breast cancer surgery by regional anesthesia and analgesia does not affect vascular endothelial growth factor and prostaglandin E2. Anesth Analg 2005; 100:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pei L, Tan G, Wang L, et al. Comparison of combined general-epidural anesthesia with general anesthesia effects on survival and cancer recurrence: a meta-analysis of retrospective and prospective studies. PLoS One 2014; 9:e114667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grandhi RK, Lee S, Abd-Elsayed A. The Relationship Between Regional Anesthesia and Cancer: A Metaanalysis. Ochsner J 2017; 17:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee BM, Singh Ghotra V, Karam JA, et al. Regional anesthesia/analgesia and the risk of cancer recurrence and mortality after prostatectomy: a meta-analysis. Pain Manag 2015; 5:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weng M, Chen W, Hou W, et al. The effect of neuraxial anesthesia on cancer recurrence and survival after cancer surgery: an updated meta-analysis. Oncotarget 2016; 7:15262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shavit Y, Terman GW, Lewis JW, et al. Effects of footshock stress and morphine on natural killer lymphocytes in rats: studies of tolerance and cross-tolerance. Brain Res 1986; 372:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beilin B, Martin FC, Shavit Y, et al. Suppression of natural killer cell activity by high-dose narcotic anesthesia in rats. Brain Behav Immun 1989; 3:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boland JW, Pockley AG. Influence of opioids on immune function in patients with cancer pain: from bench to bedside. Br J Pharmacol 2018; 175:2726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen J, Luk K, Vang D, et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br J Anaesth 2014; 113 Suppl 1:i4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cui JH, Jiang WW, Liao YJ, et al. Effects of oxycodone on immune function in patients undergoing radical resection of rectal cancer under general anesthesia. Medicine (Baltimore) 2017; 96:e7519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ní Eochagáin A, Burns D, Riedel B, et al. The effect of anaesthetic technique during primary breast cancer surgery on neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and return to intended oncological therapy. Anaesthesia 2018; 73:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly C, Buggy DJ. Opioids and tumour metastasis: does the choice of the anesthetic-analgesic technique influence outcome after cancer surgery? Curr Opin Anaesthesiol 2016; 29:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saurer TB, Ijames SG, Carrigan KA, Lysle DT. Neuroimmune mechanisms of opioid-mediated conditioned immunomodulation. Brain Behav Immun 2008; 22:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraus J. Regulation of mu-opioid receptors by cytokines. Front Biosci (Schol Ed) 2009; 1:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wigmore T, Farquhar-Smith P. Opioids and cancer: friend or foe? Curr Opin Support Palliat Care 2016; 10:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singleton PA, Mirzapoiazova T, Hasina R, et al. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth 2014; 113 Suppl 1:i103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang H, Sun M, Zhou D, et al. Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br J Anaesth 2020; 125:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 2013; 119:4103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bortsov AV, Millikan RC, Belfer I, et al. μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 2012; 116:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janku F, Johnson LK, Karp DD, et al. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol 2016; 27:2032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew B, Lennon FE, Siegler J, et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011; 112:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koodie L, Yuan H, Pumper JA, et al. Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. Am J Pathol 2014; 184:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doornebal CW, Vrijland K, Hau CS, et al. Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺ breast cancer. Pain 2015; 156:1424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afsharimani B, Baran J, Watanabe S, et al. Morphine and breast tumor metastasis: the role of matrix-degrading enzymes. Clin Exp Metastasis 2014; 31:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friesen C, Hormann I, Roscher M, et al. Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle 2014; 13:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friesen C, Roscher M, Hormann I, et al. Cell death sensitization of leukemia cells by opioid receptor activation. Oncotarget 2013; 4:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montagna G, Gupta HV, Hannum M, et al. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br J Anaesth 2021; 126:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuval JB, Lee J, Wu F, et al. Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study. Br J Anaesth 2022; 129:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med 2014; 3:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silagy AW, Hannum ML, Mano R, et al. Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. Br J Anaesth 2020; 125:e402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tai YH, Wu HL, Chang WK, et al. Intraoperative Fentanyl Consumption Does Not Impact Cancer Recurrence or Overall Survival after Curative Colorectal Cancer Resection. Sci Rep 2017; 7:10816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh TK, Jeon JH, Lee JM, et al. Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery. PLoS One 2017; 12:e0181672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz-Cambronero O, Mazzinari G, Cata JP. Perioperative opioids and colorectal cancer recurrence: a systematic review of the literature. Pain Manag 2018; 8:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamaraux-Tran TN, Piegeler T. The Amide Local Anesthetic Lidocaine in Cancer Surgery-Potential Antimetastatic Effects and Preservation of Immune Cell Function? A Narrative Review. Front Med (Lausanne) 2017; 4:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soto G, Naranjo González M, Calero F. Intravenous lidocaine infusion. Rev Esp Anestesiol Reanim (Engl Ed) 2018; 65:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piegeler T, Schläpfer M, Dull RO, et al. Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNFα-induced invasion of lung adenocarcinoma cells in vitro by blocking the activation of Akt and focal adhesion kinase. Br J Anaesth 2015; 115:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamaraux-Tran TN, Mathelin C, Aprahamian M, et al. Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial. Anticancer Res 2018; 38:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson MZ, Crowley PD, Foley AG, et al. Effect of perioperative lidocaine on metastasis after sevoflurane or ketamine-xylazine anaesthesia for breast tumour resection in a murine model. Br J Anaesth 2018; 121:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman J, Crowley PD, Foley AG, et al. Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery. Anticancer Res 2018; 38:5599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang H, Yang L, Zhu X, et al. Association between intraoperative intravenous lidocaine infusion and survival in patients undergoing pancreatectomy for pancreatic cancer: a retrospective study. Br J Anaesth 2020; 125:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cazenave L, Faucher M, Tourret M, et al. Intravenous lidocaine and cancer outcomes after radical cystectomy. Eur J Anaesthesiol 2022; 39:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubowitz JA, Cata JP, De Silva AP, et al. Volatile anaesthesia and peri-operative outcomes related to cancer: a feasibility and pilot study for a large randomised control trial. Anaesthesia 2021; 76:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forget P, Bentin C, Machiels JP, et al. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth 2014; 113 Suppl 1:i82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forget P, Vandenhende J, Berliere M, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg 2010; 110:1630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaashua L, Shabat-Simon M, Haldar R, et al. Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial. Clin Cancer Res 2017; 23:4651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cata JP, Singh V, Lee BM, et al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J Anaesthesiol Clin Pharmacol 2017; 33:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavon H, Matzner P, Benbenishty A, et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth 2018; 120:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forget P, Berlière M, Poncelet A, De Kock M. Effect of clonidine on oncological outcomes after breast and lung cancer surgery. Br J Anaesth 2018; 121:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang F, Liu H, Wang F, et al. Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. Mol Med Rep 2018; 17:5213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glasner A, Avraham R, Rosenne E, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010; 184:2449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou L, Li Y, Li X, et al. Propranolol Attenuates Surgical Stress-Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy. J Immunol 2016; 196:3460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yap A, Lopez-Olivo MA, Dubowitz J, et al. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. Br J Anaesth 2018; 121:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Childers WK, Hollenbeak CS, Cheriyath P. β-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis. Clin Breast Cancer 2015; 15:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gündisch S, Boeckeler E, Behrends U, et al. Glucocorticoids augment survival and proliferation of tumor cells. Anticancer Res 2012; 32:4251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Oliveira GS Jr, McCarthy R, Turan A, et al. Is dexamethasone associated with recurrence of ovarian cancer? Anesth Analg 2014; 118:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merk BA, Havrilesky LJ, Ehrisman JA, et al. Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer. Curr Med Res Opin 2016; 32:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang WW, Zhu WZ, Mu DL, et al. Perioperative Management May Improve Long-term Survival in Patients After Lung Cancer Surgery: A Retrospective Cohort Study. Anesth Analg 2018; 126:1666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu HC, Luo YX, Peng H, et al. Avoiding perioperative dexamethasone may improve the outcome of patients with rectal cancer. Eur J Surg Oncol 2015; 41:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopf HW, Gibson JJ, Angeles AP, et al. Hyperoxia and angiogenesis. Wound Repair Regen 2005; 13:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tertil M, Jozkowicz A, Dulak J. Oxidative stress in tumor angiogenesis- therapeutic targets. Curr Pharm Des 2010; 16:3877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowley PD, Stuttgen V, O'Carroll E, et al. Exposure to 60% oxygen promotes migration and upregulates angiogenesis factor secretion in breast cancer cells. Med Gas Res 2017; 7:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyhoff CS, Jorgensen LN, Wetterslev J, et al. Risk of new or recurrent cancer after a high perioperative inspiratory oxygen fraction during abdominal surgery. Br J Anaesth 2014; 113 Suppl 1:i74.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 117029 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29860482" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25220842" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25220842" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24996129" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23242747" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31255291" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Influence of perioperative anaesthetic and analgesic interventions on oncological outcomes: a narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27275778" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Inflammatory and Immune Responses to Surgery and Their Clinical Impact.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21141740" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Beta-adrenergic receptors in cancer: therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20381235" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28817109" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21935924" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cancer recurrence after surgery: direct and indirect effects of anesthetic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26579469" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : HIF-1αpathway: role, regulation and intervention for cancer therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25072260" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prostate cancer cell malignancy via modulation of HIF-1αpathway with isoflurane and propofol alone and in combination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27423661" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hypoxia in tissue repair and fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28741521" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hypoxia-Inducible Factors: Master Regulators of Cancer Progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22340592" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33993953" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Can anaesthetic technique influence cancer outcome? The next steps….
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31645288" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34195784" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Long-term Survival after Combined Epidural-General Anesthesia or General Anesthesia Alone: Follow-up of a Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34192298" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epidural Anesthesia-Analgesia and Recurrence-free Survival after Lung Cancer Surgery: A Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23774231" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25009196" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effect of anaesthetic technique on the natural killer cell anti-tumour activity of serum from women undergoing breast cancer surgery: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25750280" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effect of anaesthetic technique on immune cell infiltration in breast cancer: a follow-up pilot analysis of a prospective, randomised, investigator-masked study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24122989" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effects of sevoflurane on breast cancer cell function in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18685933" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Anesthetics, immune cells, and immune responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25501719" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Impact of isoflurane on malignant capability of ovarian cancer in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27028996" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Volatile anaesthetics enhance the metastasis related cellular signalling including CXCR2 of ovarian cancer cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29406185" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Differential effects of sevoflurane on the metastatic potential and chemosensitivity of non-small-cell lung adenocarcinoma and renal cell carcinoma in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29750301" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27227779" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A Systematic Review of the Modifying Effect of Anaesthetic Drugs on Metastasis in Animal Models for Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19192300" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29654781" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effects of propofol on cancer development and chemotherapy: Potential mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27866303" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25009197" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Differential effects of serum from patients administered distinct anaesthetic techniques on apoptosis in breast cancer cells in vitro: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26813135" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : [The effect of propofol and sevoflurane on the perioperative immunity in patients under laparoscopic radical resection of colorectal cancer].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23775574" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Comparison of the effects of desflurane and propofol anesthesia on the inflammatory response and s100βprotein during coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27930529" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effects of propofol and sevoflurane on perioperative immune response in patients undergoing laparoscopic radical hysterectomy for cervical cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25169512" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Influence of propofol, isoflurane and enflurance on levels of serum interleukin-8 and interleukin-10 in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27840947" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Propofol inhibits the growth and survival of gastric cancer cells in vitro through the upregulation of ING3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28426124" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Propofol suppresses LPS-induced nuclear accumulation of HIF-1αand tumor aggressiveness in non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24596379" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Propofol and bupivacaine in breast cancer cell function in vitro - role of the NET1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29103019" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Propofol induces apoptosis of breast cancer cells by downregulation of miR-24 signal pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29490000" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Propofol inhibits proliferation, migration, and invasion but promotes apoptosis by regulation of Sox4 in endometrial cancer cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28118321" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Propofol Suppresses Esophageal Squamous Cell Carcinoma Cell Migration and Invasion by Down-Regulation of Sex-Determining Region Y-box 4 (SOX4).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26250764" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14570648" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31052479" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of Perioperative Lidocaine, Propofol and Steroids on Pulmonary Metastasis in a Murine Model of Breast Cancer Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487949" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Does analgesia and condition influence immunity after surgery? Effects of fentanyl, ketamine and clonidine on natural killer activity at different ages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9428872" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The inhibitory effects of thiopental, midazolam, and ketamine on human neutrophil functions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23315866" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Ketamine used as an acesodyne in human breast cancer therapy causes an undesirable side effect, upregulating anti-apoptosis protein Bcl-2 expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26556730" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer Surgery: A Retrospective Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24857018" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The choice of anaesthetic--sevoflurane or propofol--and outcome from cancer surgery: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27066202" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29739245" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Long-Term Oncologic Outcomes for Patients Undergoing Volatile Versus Intravenous Anesthesia for Non-Small Cell Lung Cancer Surgery: A Retrospective Propensity Matching Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31171343" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in hepatectomy for hepatocellular carcinoma: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31180151" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Retrospective analysis of 1-year mortality after gastric cancer surgery: Total intravenous anesthesia versus volatile anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30376457" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Total Intravenous Anesthesia versus Inhalation Anesthesia for Breast Cancer Surgery: A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32415980" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Survival after primary breast cancer surgery following propofol or sevoflurane general anesthesia-A retrospective, multicenter, database analysis of 6305 Swedish patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32930730" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Volatile versus Total Intravenous Anesthesia for Cancer Prognosis in Patients Having Digestive Cancer Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35759394" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Volatile versus Propofol General Anesthesia and Long-term Survival after Breast Cancer Surgery: A National Registry Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30834506" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33386126" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Inhalation or total intravenous anaesthesia and recurrence after colorectal cancer surgery: a propensity score matched Danish registry-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32568845" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35051263" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Expression Profiles of Immune Cells after Propofol or Sevoflurane Anesthesia for Colorectal Cancer Surgery: A Prospective Double-blind Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26423449" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The effects of anesthesia on the morphoproteomic expression of head and neck squamous cell carcinoma: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30074934" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effect of Equipotent Doses of Propofol versus Sevoflurane Anesthesia on Regulatory T Cells after Breast Cancer Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26669824" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effects of anaesthesia on proliferation, invasion and apoptosis of LoVo colon cancer cells in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15212342" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Regional anaesthesia, local anaesthetics and the surgical stress response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15616085" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Inhibition of the stress response to breast cancer surgery by regional anesthesia and analgesia does not affect vascular endothelial growth factor and prostaglandin E2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25548913" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Comparison of combined general-epidural anesthesia with general anesthesia effects on survival and cancer recurrence: a meta-analysis of retrospective and prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29230120" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The Relationship Between Regional Anesthesia and Cancer: A Metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26250850" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Regional anesthesia/analgesia and the risk of cancer recurrence and mortality after prostatectomy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26918830" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The effect of neuraxial anesthesia on cancer recurrence and survival after cancer surgery: an updated meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3011211" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effects of footshock stress and morphine on natural killer lymphocytes in rats: studies of tolerance and cross-tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2477090" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Suppression of natural killer cell activity by high-dose narcotic anesthesia in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28593737" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Influence of opioids on immune function in patients with cancer pain: from bench to bedside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24861561" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28767570" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effects of oxycodone on immune function in patients undergoing radical resection of rectal cancer under general anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29457215" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The effect of anaesthetic technique during primary breast cancer surgery on neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and return to intended oncological therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27214644" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Opioids and tumour metastasis: does the choice of the anesthetic-analgesic technique influence outcome after cancer surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17689049" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Neuroimmune mechanisms of opioid-mediated conditioned immunomodulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19482692" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Regulation of mu-opioid receptors by cytokines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26990052" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Opioids and cancer: friend or foe?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24920011" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Increasedμ-opioid receptor expression in metastatic lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32900505" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24104703" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22433205" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27573565" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21156980" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24495739" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25734987" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24072419" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Morphine and breast tumor metastasis: the role of matrix-degrading enzymes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24626197" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23633472" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Cell death sensitization of leukemia cells by opioid receptor activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33220939" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35718564" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24692226" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32703551" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28883624" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Intraoperative Fentanyl Consumption Does Not Impact Cancer Recurrence or Overall Survival after Curative Colorectal Cancer Resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28732026" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30212256" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Perioperative opioids and colorectal cancer recurrence: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29326939" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The Amide Local Anesthetic Lidocaine in Cancer Surgery-Potential Antimetastatic Effects and Preservation of Immune Cell Function? A Narrative Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29496229" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Intravenous lidocaine infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26475807" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNFα-induced invasion of lung adenocarcinoma cells in vitro by blocking the activation of Akt and focal adhesion kinase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29277761" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29935598" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Effect of perioperative lidocaine on metastasis after sevoflurane or ketamine-xylazine anaesthesia for breast tumour resection in a murine model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30275177" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32475684" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Association between intraoperative intravenous lidocaine infusion and survival in patients undergoing pancreatectomy for pancreatic cancer: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35232940" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Intravenous lidocaine and cancer outcomes after radical cystectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33440019" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Volatile anaesthesia and peri-operative outcomes related to cancer: a feasibility and pilot study for a large randomised control trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24464611" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20435950" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28490464" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Perioperative COX-2 andβ-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29109628" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29397129" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29935555" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Effect of clonidine on oncological outcomes after breast and lung cancer surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29393410" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124103" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26969754" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Propranolol Attenuates Surgical Stress-Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29935594" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26516037" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : β-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23060545" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Glucocorticoids augment survival and proliferation of tumor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24299930" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Is dexamethasone associated with recurrence of ovarian cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26583436" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29517574" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Perioperative Management May Improve Long-term Survival in Patients After Lung Cancer Surgery: A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25744813" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Avoiding perioperative dexamethasone may improve the outcome of patients with rectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16283871" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Hyperoxia and angiogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21158725" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Oxidative stress in tumor angiogenesis- therapeutic targets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29497482" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Exposure to 60% oxygen promotes migration and upregulates angiogenesis factor secretion in breast cancer cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24860156" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Risk of new or recurrent cancer after a high perioperative inspiratory oxygen fraction during abdominal surgery.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
